PRKCA and breast carcinoma: However, activated PKCα attenuates Jagged-1-mediated Notch1 activity in ErbB2-positive breast cancer and restores trastuzumab resistance, suggesting that PKCα activity may be a potential prognostic marker for low Notch activity and increased trastuzumab sensitivity in ErbB2-positive breast cancer [111].